StockNews.AI
BBIO
StockNews.AI
148 days

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

1. BridgeBio to present cardiovascular outcomes data for acoramidis at ACC 2025. 2. Acoramidis shows improvement in heart function according to phase 3 study results. 3. Poster presentations include key findings on TTR levels and hospitalizations. 4. ATTR-CM treatment demonstrated low side effects with high tolerability. 5. BridgeBio is focused on innovative therapies for genetic diseases.

6m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical data presentations often lead to increased investor confidence. Historical instances, such as successes in other biotech companies, have resulted in stock price surges following similar announcements.

How important is it?

The significance of acoramidis data could validate BridgeBio's market position, influencing future growth. Market reactions to scientific validations are often substantial.

Why Short Term?

The upcoming presentations are immediate, likely to influence valuation quickly. Historically, biotech stocks often react within days to news from conferences like ACC.

Related Companies

TBPHALNYSRNE
March 24, 2025 07:30 ET  | Source: BridgeBio Pharma, Inc. PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in Chicago, Illinois on March 29-31, 2025. Additionally, BridgeBio was selected to share five poster presentations and two moderated posters on ATTR-CM. Flatboard Poster Presentations:Acoramidis Improves Serum TTR Levels in Patients with Wild-type or Variant Transthyretin Amyloid CardiomyopathyPresenter: Margot Davis, M.D. of Vancouver General Hospital, CADate: Monday, March 31 at 9:00 am CT/10:00 am ET Acoramidis Improves NYHA Class at Month 30 Versus Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM StudyPresenter: Kevin Alexander, M.D. of Stanford University School of Medicine, USADate: Sunday, March 30 at 1:30 pm CT/2:30 pm ET In Participants Treated with Acoramidis, Addition of Concomitant Tafamidis Did Not Further Increase Serum TTR LevelsPresenter: Mathew Maurer, M.D. of Columbia University Irving Medical Center, USADate: Monday, March 31 at 9:00 am CT/10:00 am ET Robustness of Primary Endpoint Efficacy Results with Acoramidis in ATTR-CM in the ATTRibute-CM Study: Pre-specified NT-proBNP Sensitivity AnalysesPresenter: Jan Griffin, M.D. of Medical University of South Carolina, USADate: Sunday, March 30 at 1:30 pm CT/2:30 pm ET Acoramidis-mediated Early Increase in Serum Transthyretin Level Reduces Cardiovascular-related Hospitalizations and Mortality: Insights from the ATTRibute-CM StudyPresenter: Nitasha Sirwat, M.D. of UChicago Medicine, USADate: Monday, March 31 at 9:00 am CT/10:00 am ET Moderated Posters:Primary Endpoint Efficacy Results in the ATTRibute-CM Study: Pre-specified Sensitivity Analyses Addressed Tafamidis UsePresenter: Daniel P. Judge, M.D. of Medical University of South Carolina, USADate: Saturday, March 29 at 10:06 am CT/11:06 am ET Geographic Healthcare Disparities and Diagnostic Trends Among Patients with Transthyretin Amyloid CardiomyopathyPresenter: Joshua Mitchell, M.D., Washington University School of Medicine in St. Louis, USADate: Saturday, March 29 at 10:54 am CT/11:54 am CT About Attruby™ (acoramidis) Attruby is the first near-complete (≥90%) stabilizer of Transthyretin (TTR) approved in the U.S. for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. Attruby was generally well-tolerated. The most common side effects were mild and included diarrhea and abdominal pain that were resolved without drug discontinuation. BridgeBio offers an extensive suite of programs to help patients access our medicines. About BridgeBioBridgeBio Pharma (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook. BridgeBio Media Contact:Bubba Murarka, EVP Communicationscontact@bridgebio.com (650)-789-8220

Related News